Interesting webinar hosted by @Airfinity on From Science to Strategy: Making RSV, hMPV, and PIV vaccines work in the real world. The session discusses the challenges of integrating combinations vaccines, the impact of seasonality on rollout strategies and the global severe burden of respiratory viruses.
👉 We are delighted that hVIVO’s presentation by Dr Andrew Catchpole on results from our hMPV pilot HCT trial at the @iRSVsociety conference in Brazil is mentioned at 1:00:40
Tune into full webinar here:
https://t.co/BhXPBPHysO
#HVO #hMPV #Webinar #CHIM #Healthcare #Vaccines
Influenza positivity rose by 7% in outpatients and 5% in hospitalised patients since the week before, while RSV and hMPV increased marginally. For outpatients, influenza is the leading cause amongst all ages while hMPV is the second leading cause in children under 14.
Is #hMPV causing the outbreak of respiratory infections in #China? The latest data suggests it's largely driven by influenza. Testing of outpatients show 6% had hMPV, compared to 30% with influenza.
#humanmetapneumovirus#globalhealth#respiratoryvirus
@Airfinity predicts the risk of H5N1 & seasonal influenza reassortment will increase five-fold this winter… experts urging US to consider vaccines for poultry/dairy workers https://t.co/OFUvaTAJQR
What's new with bird flu and H5N1 pandemic prevention? Join me, @florian_krammer, Hanna Nohynek, and Bob Kadlec at this webinar to find out.
October 10, 10 am ET, free registration at the link below!
https://t.co/7Rq4t8SZ7J
Thanks to @Airfinity & CSL Seqirus for organizing.
The cost of #Wegovy to prevent one stroke in the US is double what’s paid by Britain’s health service, reveals new analysis by Airfinity.
Read our feature in @Bloomberg to find out more.
https://t.co/gUi4M8Snzp
Join our @ScienceUnga Webinar: Data for Pandemic Preparedness: New approaches for medical countermeasure (MCM) delivery
Live next Wednesday 18th September 2024, 3pm ET/ 8pm BST.
Register for free through the UNGA Science Summit online portal below.
https://t.co/7M2NFxTNoX
As featured in the @FT today, Airfinity has reduced its sales projections for vaccines against Respiratory Syncytial Virus (#RSV) for older adults in the US from $4.7bn per year to $1.7bn by 2030.
Reach out to find out more about our estimate or the burden of RSV.
“There is a 27.5% chance of a COVID-like pandemic in the next 10 years." – @rasbech, Founder and CEO of @Airfinity, at the 2024 Copenhagen Democracy Summit.
Watch the full session: https://t.co/Xa8R0nlXEY
Has the pandemic fundamentally changed us or the pathogens which surround us?
Our study, featured in @Telegraph, shows over 40 countries or territories have reported at least one infectious disease resurgence that’s 10-fold or more over their pre-pandemic baseline.
Has the pandemic made us sicker?
The momentous two year event had a profound impact on health ecosystems globally – but its legacy goes beyond a possible immunity debt.
Find out more below 👇
https://t.co/0ylf3AwHwV
Is avian influenza becoming less deadly?
New analysis shows that case fatality rate (CFR) has dropped to a 33% average over the last 9 years, from 62% pre-2015.
A lower CFR may signal that #H5N1 is becoming more suited to human-human infection.
Reach out to learn more.
Over 40 countries have reported at least one #infectious#disease resurgence that's 10-fold or more over their pre #pandemic baseline.
Read Airfinity and @business' collaborative report on global disease resurgence below.
https://t.co/nUdkES8oRO
New analysis by Airfinity shows there has been a 300% rise in approved new #cancer treatments in the last two decades, with the US Cancer Moonshot Goal achievable by 2048.
Click below to access the full findings on global cancer #disease burden.
https://t.co/y97Zb2UsgQ
Don't miss this by @Airfinity founder @rasbech
Excellent read and charts on why need to go further than a Pandemic Treaty if we are to properly protect ourselves from future threats.
The good news: democracies did best with Covid...
https://t.co/QEruzuKzTy
"The West should be on a war footing for the next pandemic," writes Rasmus Bech Hansen, founder of @Airfinity
Covid-19 was not a once in a lifetime risk. Western allies need more than a global treaty to protect themselves from the next crisis.
https://t.co/PjqEUGzAVG
Today, the @IFPMA release 'From resistance to resilience: What could the future antibiotic pipeline look like?'. Our analysis shows a more robust pipeline could reduce the potential burden on HICs by up to 63%, highlighting the desperate need for new incentives. Read more below.
New report from @IFPMA discusses future of the antibiotic pipeline over the next 10 years, based on modelling done with @Airfinity. Data shows that the introduction of effective pull incentives by 2025 would see a substantial positive impact:
➡ https://t.co/zTTbhnGpTC
Airfinity’s latest analysis reveals that #Wegovy could prevent up to 3.1 million cases of #CKD in the US by 2030, with a high coverage scenario among patients with class II and class III #obesity. Learn more in our free weekly obesity market newsletter: https://t.co/TQeD2uHE7l